We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.91B
AUM Growth
-$2.06B
Cap. Flow
+$62M
Cap. Flow %
0.63%
Top 10 Hldgs %
40.04%
Holding
153
New
17
Increased
26
Reduced
29
Closed
21

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$123M
2
WMGI
Wright Medical Group Inc
WMGI
+$120M
3
LLY icon
Eli Lilly
LLY
+$107M
4
HCA icon
HCA Healthcare
HCA
+$72.7M
5
DVAX
Dynavax Technologies
DVAX
+$70M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$161M
2
SHPG
Shire pic
SHPG
+$153M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$120M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$119M
5
GILD icon
Gilead Sciences
GILD
+$79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Financials 0.24%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
26
Agilent Technologies
A
$39.8B
$121M 1.23%
3,539,000
-129,000
-4% -$4.88M
PFE icon
27
Pfizer
PFE
$144B
$118M 1.19%
3,966,202
+748,340
+23% +$24M
IRWD icon
28
Ironwood Pharmaceuticals
IRWD
$614M
$117M 1.18%
13,404,322
-1,404,263
-9% -$13.1M
CYH icon
29
Community Health Systems
CYH
$393M
$116M 1.17%
3,291,442
+1,440,142
+78% +$66M
INSY
30
DELISTED
Insys Therapeutics, Inc.
INSY
$116M 1.17%
4,081,800
+1,458,800
+56% +$53.7M
ISRG icon
31
Intuitive Surgical
ISRG
$128B
$110M 1.11%
2,151,000
-560,700
-21% -$31.8M
ESRX
32
DELISTED
Express Scripts Holding Company
ESRX
$109M 1.1%
1,342,000
– –
LLY icon
33
Eli Lilly
LLY
$1.09T
$106M 1.07%
+1,272,000
New +$107M
BLUE
34
DELISTED
bluebird bio
BLUE
$102M 1.03%
91,783
+17,802
+24% +$32.5M
CLVS
35
DELISTED
Clovis Oncology, Inc.
CLVS
$102M 1.03%
1,105,900
+100,700
+10% +$8.71M
MGLN
36
DELISTED
Magellan Health Services, Inc.
MGLN
$102M 1.03%
1,833,000
+382,300
+26% +$23.1M
AGN.PRA
37
DELISTED
Allergan plc
AGN.PRA
$98.3M 0.99%
104,200
– –
PBYI icon
38
Puma Biotechnology
PBYI
$404M
$90.1M 0.91%
1,195,500
+254,700
+27% +$24.1M
ISEE
39
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$77.9M 0.79%
1,923,500
+248,900
+15% +$13.2M
MNK
40
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$75M 0.76%
1,173,000
+378,000
+48% +$37.4M
NUVA
41
DELISTED
NuVasive, Inc.
NUVA
$71.7M 0.72%
1,487,000
– –
GKOS icon
42
Glaukos
GKOS
$9.04B
$70.1M 0.71%
2,897,937
– –
TSRO
43
DELISTED
TESARO, Inc.
TSRO
$69.6M 0.7%
1,735,200
-336,280
-16% -$18.4M
AFFX
44
DELISTED
Affymetrix Inc
AFFX
$64.1M 0.65%
7,511,000
– –
DVAX
45
DELISTED
Dynavax Technologies
DVAX
$60.7M 0.61%
+2,472,200
New +$70M
INSM icon
46
Insmed
INSM
$22.6B
$58.4M 0.59%
3,145,301
+1,436,801
+84% +$35.9M
ARRY
47
DELISTED
Array Biopharma Inc
ARRY
$45.9M 0.46%
10,060,500
– –
PTLA
48
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$42M 0.42%
984,700
+134,000
+16% +$6.47M
SRRA
49
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$40.8M 0.41%
+49,749
New +$56.1M
OTIC
50
DELISTED
Otonomy, Inc.
OTIC
$40.2M 0.41%
2,256,398
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2015 Portfolio in Review

As of Q3 2015, OrbiMed held 153 positions worth $9.91B, down 17% from $12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2015 filing shows 17 new, 26 increased, 29 reduced and 21 closed positions. Its largest new stake was Eli Lilly: 1,272,000 shares worth $106M. The largest sale was MEDIVATION, INC., an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2015 buy was Eli Lilly: 1,272,000 shares worth $106M.
  • OrbiMed added most to Teva Pharmaceuticals in Q3 2015, an estimated $123M increase.
  • OrbiMed's biggest Q3 2015 reduction was Shire pic, cutting an estimated $153M.
  • OrbiMed fully exited MEDIVATION, INC. in Q3 2015, selling an estimated $161M.
  • OrbiMed's ten largest holdings make up 40% of its $9.91B portfolio in Q3 2015.
  • OrbiMed opened 17 new positions and closed 21 in Q3 2015.
  • OrbiMed's portfolio value fell 17% quarter-over-quarter to $9.91B.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.